Clinical Trial Update: A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C [Phase 2]

View source ↗

Summary

Phase 2 trial assessing sustainability of effects of SYN-010 in Irritable Bowel Syndrome with Constipation (IBS-C); study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• SYN-010

Snippet

Sponsor: Theriva Biologics, Inc. | Conditions: Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 2 | Status: COMPLETED | Results posted: 2017-03-08